Introduction You hear the words "glioblastoma" and the statistics hit immediately. Most people with this type of brain cancer survive for less than 2 years. Standard radiation and temozolomide chemotherapy can buy time, but the tumor nearly always returns. That grim reality is what makes the shift toward personalized immunotherapy matter in 2026. Instead of a one-size-fits-all poison, researchers now engineer treatments that match your tumor's specific genetic mutations, trai

When multiple myeloma returns after initial treatment, accessing specialized expertise becomes critical. A second opinion can reveal novel therapies, clinical trials, and treatment sequencing strategies that community oncologists may not routinely offer. Key Takeaways Gather thorough medical records, FISH panels, imaging, treatment timelines, before contacting specialists to enable accurate relapse assessment Target specialists with high relapsed-myeloma case volume, CAR-T th